SESN News and Press, Sesen Bio Inc. From 02/14/23

Sesen Bio ( NASDAQ: SESN ) added ~11% pre-market Tuesday in reaction to an agreement with two key shareholders to obtain support for its pending merger with privately held Carisma Therapeutics under amended terms. The shareholders, Bradley Radoff and Michael Torok, who own approxi...

Amend Merger Agreement to Increase Expected Special Cash Dividend to $75 Million and Extend Contingent Value Right for Vicineum to March 31, 2027 Bradley L. Radoff and Michael Torok to Vote Shares in Support of Transaction Michael Torok to Join Carisma Board of Directors as Only S...

Highlights Board’s Robust Strategic Review Process and Unanimous Determination that Carisma Merger Maximizes Value for Stockholders Urges Stockholders to Vote “FOR” Transaction Ahead of Special Meeting of Stockholders on March 2, 2023 Sesen Bio, Inc. (NASDAQ...

Sesen Bio ( NASDAQ: SESN ) has received a Nasdaq delisting notice as its share price has fallen below $1. The company said that the notice emphasized the need for its planned merger with Carisma Therapeutics. Otherwise, it faces deregistration of its stock and a court-managed dis...

Company Remains Focused on Significant Benefits of Pending Merger with Carisma Delisting Notice Underscores Potential for Corporate Dissolution if Merger is not Approved by Stockholders Sesen Bio, Inc. (Nasdaq: SESN) (“Sesen Bio” or the “Company”) tod...

Company Calls Out Misrepresentations from Investor Group Sesen Bio, Inc. (Nasdaq: SESN) today issued the following statement reiterating the Company’s confidence in, and commitment to, the pending merger with Carisma Therapeutics Inc. (Carisma) in response to the release issued y...

Discloses Recent Offer to Provide Paid Advisory Roles to Messrs. Radoff and Torok – Major Stockholders of Sesen Bio – in Exchange for Their Support of the Proposed Merger of Sesen Bio and Carisma Reiterates Intent to Vote AGAINST the Proposed Merger Bradl...

Schedules March 2, 2023, Special Meeting of Stockholders to Vote on Merger Launches www.SesenBioandCarisma.com , Providing Additional Information for Stockholders Sesen Bio, Inc. (Nasdaq: SESN) today announced that it has filed definitive proxy materials with the U.S. Securi...

Summary Lead drug candidate improves on listed standard treatment. Marketing authorization is within reach in 5 months, but the FDA might balk even with a pre-approved trial design. The company has money to at least last that long, but approval isn't a sure thing. Immunity...

Calls on Board to Stop Wasting Corporate Resources and Hold a Stockholder Vote as Soon as Possible Questions the Board’s Apparent Desire to Keep Stockholders in the Dark on Key Details Bradley L. Radoff and Michael Torok (together with their affiliates, the “...